GlassScriptPhysician profile
Taylor Starks
NPI 1417684788
$3,017.65
in general payments reported to CMS, 2019-2025
36 companies · $126 in 2025
The $126 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $511 · 2023: $1,808 · 2024: $572 · 2025: $126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,506 · Education: $1.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,505.80 |
| Education | $1.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $514.61 | 2023-2025 | Azstarys, Adlarity |
| Ironshore Pharmaceuticals INC. | $466.61 | 2023-2024 | Jornay Pm |
| Emd Serono, INC. | $157.82 | 2023 | Mavenclad |
| Sk Life Science, INC. | $143.15 | 2023 | Xcopri |
| Teva Pharmaceuticals USA, INC. | $138.92 | 2022-2023 | Austedo |
| Biogen, INC. | $133.80 | 2022-2023 | Vumerity, Tysabri, Tysabri |
| Lilly USA, LLC | $123.36 | 2022-2023 | Amyvid, Emgality |
| Noven Therapeutics, LLC | $116.86 | 2023-2025 | Xelstrym |
| Abbvie INC. | $106.48 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $103.48 | 2022 | |
| Noven Pharmaceuticals, INC. | $96.19 | 2023 | Xelstrym |
| Celgene Corporation | $93.94 | 2022-2023 | Zeposia |
| Genentech USA, INC. | $73.18 | 2023 | Ocrevus, Enspryng |
| Ucb, INC. | $68.11 | 2023 | Briviact |
| Argenx US, INC. | $61.85 | 2023 | Vyvgart |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Upsher-Smith Laboratories LLC | $61.17 | 2022 | |
| Pfizer INC. | $60.41 | 2023 | |
| Avion Pharmaceuticals | $55.30 | 2022-2023 | Dhivy |
| Takeda Pharmaceuticals U.S.A., INC. | $39.73 | 2022-2023 | Gammagard |
| Otsuka America Pharmaceutical, INC. | $38.47 | 2023 | Nuedexta |
| Janssen Pharmaceuticals, INC | $35.91 | 2022 | |
| Merz Pharmaceuticals, LLC | $34.11 | 2023 | Xeomin |
| Neos Therapeutics, LP | $31.19 | 2024 | Adzenys Xr-Odt |
| Novartis Pharmaceuticals Corporation | $26.87 | 2023 | |
| Grifols USA, LLC | $25.29 | 2023 | Gamunex-C |
| Tris Pharma INC | $23.93 | 2025 | Dyanavel Xr |
| Banner Life Sciences, LLC | $23.22 | 2023 | |
| Collegium Pharmaceutical, INC. | $21.00 | 2025 | Jornay Pm |
| Avanir Pharmaceuticals, INC. | $20.53 | 2022 | |
| Aprecia Pharmaceuticals, LLC | $19.00 | 2022 | |
| Alexion Pharmaceuticals, INC. | $18.22 | 2022 | |
| Mdd US Operations, LLC | $18.04 | 2023 | Xadago, Apokyn |
| Acadia Pharmaceuticals INC | $17.99 | 2023 | Daybue |
| Jazz Pharmaceuticals INC. | $17.43 | 2023 | Epidiolex |
| Ipsen Biopharmaceuticals, INC | $16.34 | 2023 | Dysport |
| Genzyme Corporation | $15.14 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Starks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.